# Amdocs Limited (DOX) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Technology / Software. Price $62.43, market value $6.5 billion.

## Valuation
- **P/E (trailing): 14.8×** (5-yr avg 16.4×, 3-yr avg 17.6×). Amdocs Limited trades at 14.8× trailing earnings, close to its own five-year average of 16.4×. The Technology median in the September 2026 study was 32.1×. Forward P/E is 6.8×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.36**. A PEG of 0.36 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 1.4×**. Each dollar of revenue is priced at 1.4×.
- **Price / book: 2.0×**. The shares trade at 2.0× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 8.4×**. Enterprise value is 8.4× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 9.8%** (5-yr avg 7.1%). Free cash flow equals 9.8% of the market value, above its five-year average of 7.1%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 6.7%**. The inverse of the P/E: 6.7% of the price is earned each year.

## Profitability
- **Gross margin: 38.3%**. Amdocs Limited keeps 38.3% of revenue after the direct cost of what it sells.
- **Operating margin: 17.8%**. 17.8% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 12.5%**. 12.5% of each dollar of sales reaches the bottom line.
- **Return on equity: 16.5%**. 16.5% on shareholders' equity is solid.
- **Return on invested capital: 16.5%**. Return on all capital, debt included, is 16.5%: comfortably above what that capital costs.
- **Return on assets: 7.3%**. Each dollar of assets produces 7.3% of profit.

## Growth
- **Revenue growth (1 yr): -9.4%** (3-yr -0.3%/yr, 5-yr 1.7%/yr). Revenue fell 9.4% over the last year, against 1.7% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 18.8%** (3-yr 4.4%/yr, 5-yr 6.4%/yr). Earnings per share rose 18.8%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 6.8%/yr**. Free cash flow has compounded at 6.8% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.24**. Debt is 0.24 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.6×**. It would take 0.6 years of operating earnings to repay net borrowings, within the comfortable range.
- **Interest coverage: 17.6×**. Operating profit covers interest 17.6× over, a safe margin.
- **Current ratio: 1.17** (quick 1.17). Current assets cover the next year's liabilities 1.17 times.
- **Altman Z-score: 3.37**. A Z-score of 3.37 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 3.64%** ($2.19 per share, trailing). Amdocs Limited yields 3.64%, an income-level yield.
- **Payout ratio: 40%** (36% of free cash flow). 40% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 14**. 14 straight years of increases, a record that survived at least one recession.
- **Dividend growth (5 yr): 9.9%/yr** (1-yr 10.0%). The dividend has grown 9.9% a year over five years.
- **Shareholder yield: 12.3%**. Dividends plus net buybacks return 12.3% of the market value a year.

## Price and momentum
- **Total return (1 yr): -22.6%** (YTD -19.5%, 3-mo 14.8%). The shares are down 22.6% over twelve months including dividends.
- **From 52-week high: -27.1%** (25.5% above the low). Trading 27% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 65**. An RSI of 65 is neutral.
- **Beta (1 yr): 0.26** (volatility 29%). Beta of 0.26 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=DOX · Page: https://foliofundamentals.com/stocks/dox

Not investment advice.